Showing results (21-30 of 39) with videos related to

Sort By:
Pageof 4
Journal of Neurochemistry|September 3, 2004
Conserved residues within the putative active site of gamma-secretase differentially influence enzyme activity and inhibitor bindingJonathan D J Wrigley, Emma J Nunn, Omar Nyabi, et al.
FEBS Letters|October 12, 2013
Generation and characterization of a rabbit monoclonal antibody site-specific for tau O-GlcNAcylated at serine 400Andrew Cameron, Brandy Giacomozzi, John Joyce, et al.
The Journal of Biological Chemistry|December 5, 2012
The role of γ-secretase activating protein (GSAP) and imatinib in the regulation of γ-secretase activity and amyloid-β generationIshrut Hussain, Julien Fabrègue, Laurence Anderes, et al.
Nature Communications|August 3, 2013
Alzheimer's disease mutations in APP but not γ-secretase modulators affect epsilon-cleavage-dependent AICD productionMitko Dimitrov, Jean-René Alattia, Thomas Lemmin, et al.
The Journal of Biological Chemistry|December 23, 2004
Functional overexpression of gamma-secretase reveals protease-independent trafficking functions and a critical role of lipids for protease activityJonathan D J Wrigley, Irina Schurov, Emma J Nunn, et al.
The Journal of Biological Chemistry|July 2, 2023
Pathogenic Aβ production by heterozygous PSEN1 mutations is intrinsic to the mutant protein and not mediated by conformational hindrance of wild-type PSEN1Vanessa Kurth, Isabella Ogorek, Carolina Münch, et al.
Biochemistry|July 9, 2003
In vitro characterization of the presenilin-dependent gamma-secretase complex using a novel affinity ligandDirk Beher, Michael Fricker, Alan Nadin, et al.
Bioorganic & Medicinal Chemistry Letters|February 4, 2006
The geminal dimethyl analogue of Flurbiprofen as a novel Abeta42 inhibitor and potential Alzheimer's disease modifying agentNicholas Stock, Benito Munoz, Jonathan D J Wrigley, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|November 15, 2025
Safety, Tolerability, Pharmacokinetics, and Brain Target Occupancy of the OGA Inhibitor ASN90 in Healthy ParticipantsRolf Pokorny, J Michael Ryan, Khalid Abd-Elaziz, et al.
Journal of Medicinal Chemistry|May 30, 2003
Design and synthesis of highly potent benzodiazepine gamma-secretase inhibitors: preparation of (2S,3R)-3-(3,4-difluorophenyl)-2-(4-fluorophenyl)-4- hydroxy-N-((3S)-1-methyl-2-oxo-5- phenyl-2,3-dihydro-1H-benzo[e][1,4]-diazepin-3-yl)butyramide by use of an asymmetric Ireland-Claisen rearrangementIan Churcher, Susie Williams, Sonia Kerrad, et al.
Pageof 4